Insulet Corporation
149.01USD
+0.8900 (+0.60%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on PODD.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 1.1B | 1.7B | 2.1B | 2.7B | 3.3B | 3.7B |
| Q1 | 247.0M | 261.3M | 441.7M | 569.0M | 761.7M | — |
| Q2 | 243.9M | 396.5M | 488.5M | 649.1M | 801.7M | — |
| Q3 | 281.9M | 432.7M | 543.9M | 706.3M | 832.6M | — |
| Q4 | 282.6M* | 509.8M* | 597.5M* | 783.8M* | 893.7M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | .070 | 2.94 | 5.78 | 3.48 | 6.51 | 7.72 |
| Q1 | .400 | .340 | .730 | .500 | 1.30 | — |
| Q2 | -.500 | .390 | 2.59 | .320 | 1.37 | — |
| Q3 | -.080 | .740 | 1.08 | 1.24 | 1.59 | — |
| Q4 | .243* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| 1.40* |
| 1.36* |
| 1.41* |
| 1.85 |
| — |
Debt level and coverage